Info

Agensys' management team offers in-depth experience in business and science and a track record of significant accomplishment. Donald B. Rice, Ph.D. - Chairman, President and CEO. A founder of Agensys, Dr. Rice was President and COO of Teledyne, Inc. from 1993-1996. He served as Secretary of the Air Force from 1989-1993 and President and CEO of the RAND Corporation from 1972-1989. Dr. Rice serves on the Board of Directors of Wells Fargo & Company, Vulcan Materials Company, and Chevron Corporation. He served as a director of Amgen, Inc., from 2000 -2007 and, until its sale to Johnson & Johnson, he also served as Chairman of the Board of Directors of Scios Inc. Dr. Rice received a BS degree in Chemical Engineering from the University of Notre Dame, an MS in Industrial Management from Purdue University, and a Ph.D. in Economics, also from Purdue. Dr. Rice serves as a Trustee of the RAND Corporation and Chairman of the Board of Governors of the RAND Graduate School, and served previously on the Commission on National Security/21st Century, the National Science Board, and the Defense Science Board. He is the recipient of numerous awards, including five honorary doctorates. Aya Jakobovits, Ph.D. - Senior Vice President, Technology and Corporate Development, and Chief Scientific Officer. Dr. Jakobovits joined Agensys in 1999 as Vice President of Research after serving as Director of Discovery Research and Principal Scientist at Abgenix since it's founding in 1996. At Abgenix, Dr. Jakobovits led the development of the XenoMouse® technology and its utilization for production of therapeutic fully human monoclonal antibodies. She also served as a member of Abgenix' management team and business operation committee. Dr. Jakobovits is co-inventor and holds 13 issued patents covering the XenoMouse® and related antibody technology. Prior to Abgenix, Dr. Jakobovits was with Cell Genesys, Inc., where she was a scientist founder and served in a number of positions from 1989-1996, most recently as Director of Molecular Immunology. She received a BSc in Chemistry from the Hebrew University in Jerusalem, Israel and an MSc in Chemistry and PhD in Life Sciences from the Weizmann Institute of Science in Rehovot, Israel. Dr. Jakobovits did her post-doctoral work at the University of California, San Francisco and Genentech, Inc. She has authored more than 40 scientific publications in major journals. Paul G. Kanan - Vice President of Operations and Chief Financial Officer. Prior to joining Agensys in 2001, Mr. Kanan was President and CEO of Pacific Biometrics, a company developing non-invasive diagnostic products that he co-founded in 1993. He is also a co-founder of CEO Advisors, Inc., a healthcare consulting firm and served as that organization's President from 1991-1993. From 1988-1991, Mr. Kanan was President and CEO of Oncotech, Inc., a specialty laboratory providing tumor drug testing for cancer patients. Mr. Kanan was employed by Baxter Healthcare Corporation in a variety of positions from 1976-1988. His most recent position at Baxter was President of the Chemotherapy Service Division, a business he conceived and launched that reached $60 million in revenue in slightly over two years. Other experience at Baxter included Corporate Finance, Corporate Strategy and International Marketing. Mr. Kanan received a BS in Engineering from the University of Michigan and an MBA from Harvard University. Christopher J. Morl - Vice President, Business Development. Mr. Morl joined Agensys in 2002 from GlaxoSmithKline where from 2001 he led the integration of the GlaxoWellcome and SmithKline Beecham businesses in China / Hong Kong. From 1998 to 2001 Mr. Morl was General Manager of SmithKline Beecham (Tianjin) Ltd. a US$71 million joint venture investment in the People's Republic of China. Prior to relocating to China in 1998, Mr. Morl held positions with SmithKline Beecham in Business Development, Marketing and R&D. Mr. Morl received a BSc in Applied Biology with Honors in Pharmacology from the University of London and a MBA from the Cranfield School of Management (UK). Martha E. Vincent, Ph.D., FACCP - Vice President, Clinical Research and Development. Dr. Vincent joined Agensys in 2004 after spending over 17 years at Amgen Inc. At Amgen, Dr. Vincent was Vice President of Medical Affairs where she led the development of all Amgen's marketed products from 2000 - 2004. The Medical Affairs organization was newly established and focused on planning and executing non-registrational studies. Prior to leading the Medical Affairs organization, Dr. Vincent was Vice President of Clinical Development where she led the clinical development of all Amgen's preclinical and clinical products from 1995 - 2000. Dr. Vincent was instrumental in building the clinical development organization, leading and executing all registrational studies US and ex-US, and preparing international registrations to regulatory authorities worldwide. Dr. Vincent was the recipient of the Science and Technology Award from Iowa State University in 2003, the Deborah Award from the Israel Cancer Research Fund in 1998, the Leadership America Award from the Women of Action in 1997, and the Distinguished Alumnus Award from New Jersey Medical School in 1992. Dr. Vincent received a BS in Biology and Education from Iowa State University and a PhD in Pharmacology from the University of Medicine and Dentistry of New Jersey, New Jersey Medical School. She completed a post-doctoral fellowship at Thomas Jefferson University in Philadelphia . She has authored more than 50 scientific publications in major journals. Alan C. Mendelson, J.D. - Partner with Latham & Watkins LLC, serves as Agensys' Corporate Secretary and Corporate Counsel. Mr. Mendelson is well known for his representation of biotechnology, medical device, and other life science companies, stemming from his organization and representation of Amgen. In 1998 and 1999, he was named by California Business Law as one of California's 100 Most Influential Lawyers, and the National Law Journal listed Mr. Mendelson as one of the country's 100 Most Influential Lawyers in 1994 and 1997.